MLTX MoonLake Immunotherapeutics
Pharmaceutical Preparations · Nasdaq · SEC CIK 1821586 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-29.9%
TTM EPS YoY-9.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-81.6%
ROA-57.3%
ROIC (approx.)-384.1%
Asset turnover—
Leverage & solvency
Liabilities / assets29.4%
Debt / equity0.26x
Current ratio9.13x
Interest coverage-28.98x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $202.86M | $112.77M |
| SG&A expense | $41.97M | $30.32M |
| Operating income | -$244.83M | -$143.09M |
| Interest expense | $7.25M | $0 |
| Pretax income | -$229.71M | -$120.96M |
| Income tax | $611,000 | $282,000 |
| Net income | -$227.32M | -$118.94M |
| EBITDA | -$242.22M | -$141.71M |
| EPS (basic) | -3.53 | -1.89 |
| EPS (diluted) | -3.53 | -1.89 |
| Weighted avg. shares (diluted) | 64.46M | 62.87M |
| Balance sheet | ||
| Cash & equivalents | $334.52M | $180.43M |
| Short-term investments | $59.45M | $267.60M |
| Current assets | $421.69M | $474.29M |
| PP&E, net | $577,000 | $722,000 |
| Total assets | $424.43M | $477.93M |
| Current liabilities | $45.48M | $22.46M |
| Long-term debt | $74.10M | $0 |
| Total debt | $74.10M | $0 |
| Total liabilities | $119.95M | $24.54M |
| Shareholders' equity | $304.48M | $446.82M |
| Net debt | -$260.42M | -$180.43M |
| Cash flow statement | ||
| Operating cash flow | -$196.01M | -$116.59M |
| Capital expenditure | $35,000 | $520,000 |
| Free cash flow | -$196.04M | -$117.11M |
| Investing cash flow | $202.99M | -$205.60M |
| Financing cash flow | $146.00M | $51.31M |
| Depreciation & amortization | $2.62M | $1.39M |
| Stock-based compensation | $12.90M | $7.28M |
| Share buybacks | — | $50 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.